Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties

Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.